Edgar Filing: CELL THERAPEUTICS INC - Form 4

CELL THER Form 4 June 07, 2013	APEUTICS INC										
FORM	1								OMB AF	PROVAL	
	TATES S	SECURITIES AND EXCHANGE CO Washington, D.C. 20549					COMMISSION	OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. Form 4 or		FATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES						Expires: January 31 2005 Estimated average burden hours per response 0.5			
Form 5 Filed pursuant to obligations may continue. Section 17(a) of the			Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Section) of the Investment Company Act of 1940								
(Print or Type R	esponses)										
SINGER JACK W Sy			2. Issuer Name and Ticker or Trading Symbol CELL THERAPEUTICS INC [CTIC]					5. Relationship of Reporting Person(s) to Issuer			
								(Check all applicable)			
(Last) (First) (Middle) 3. D (Mc			Date of Earliest Transaction Ionth/Day/Year) 5/05/2013					X Director 10% Owner X Officer (give title Other (specify below) EVP, Global Medical Affairs			
	(Street) 4. If Ame Filed(Mon				te Original			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 			
SEATTLE, V	WA 98121							Form filed by M Person			
(City)	(State) (A	Zip)	Table	e I - Non-D	erivative S	Securit	ies Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)		Date, if	3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)			Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)				
				Code V	Amount	or (D)	Price	Transaction(s) (Instr. 3 and 4)			
Common Stock	06/05/2013			S	10,000	D	\$ 1.26	701,035	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. of Derivative Securities Acquired (A) or			7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo
				Disposed of (D) (Instr. 3,						Trans (Instr
				4, and 5)		F • 4		Amount or		
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Number of Shares		
D										

Edgar Filing: CELL THERAPEUTICS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
SINGER JACK W 3101 WESTERN AVENUE SUITE 600 SEATTLE, WA 98121	Х		EVP, Global Medical Affairs				
Signatures							
Louis A. Bianco, Attorney-in-fact for Jac Singer	06/07/2013						
<u>**</u> Signature of Reporting Person		Ι	Date				
Explanation of Respons	ses:						

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.